Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2938 in Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289Phase 2Active, not recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQC2938 in chronic obstructive pulmonary disease (COPD), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Mar 2025; status: active, not recruiting.
02
Drugs
TQC2938
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06789289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789289.